

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



SciClone Pharmaceuticals (Holdings) Limited

賽生藥業控股有限公司 *

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 6600)

**SUPPLEMENTAL ANNOUNCEMENT
IN RELATION TO THE ANNUAL REPORT
FOR THE YEAR ENDED 31 DECEMBER 2020**

Reference is made to the annual report of SciClone Pharmaceuticals (Holdings) Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) for the year ended December 31, 2020 (the “**2020 Annual Report**”). Unless otherwise defined, capitalised terms used herein shall bear the same meanings as those defined in the 2020 Annual Report.

In addition to the information provided in the 2020 Annual Report, the Board would like to provide the following additional information pursuant to Paragraph 26(2) of Appendix 16 to the Listing Rules in relation to the Group’s pension obligations as stated in Note 2.19(b) headed “Summary of Significant Accounting Policies” to the consolidated financial statements on page 122 of the 2020 Annual Report.

The Group’s subsidiaries operating in Mainland China have to make contributions to staff retirement schemes managed by local government authorities in accordance with the relevant rules and regulations. Contributions to these schemes are charged to the consolidated statements of comprehensive income as and when incurred. The Group has no legal or constructive obligations to pay further contributions once the contributions are paid by the Group in compliance with the relevant rules and regulations. The local government authorities are responsible for the entire retirement scheme obligations payable to the retired employees. Contributions made to these schemes vest immediately.

The Group also participates in the Mandatory Provident Fund Scheme (“**MPF Scheme**”) in Hong Kong. The assets of the MPF Scheme are held in a separate trustee-administered fund. Both the Group and the employees employed by the Group in Hong Kong are required to contribute to the scheme monthly. The Group has no further payment obligations once the contributions have been paid. The Group’s contributions to the MPF Scheme are expensed as incurred.

No forfeited contributions by the Group on behalf of its employees who left the schemes prior to vesting fully in such contributions (2019: nil) were utilized during the year ended December 31, 2020, leaving HKD309,059.31 (equivalent to RMB260,116.68) (2019: HKD309,059.31, equivalent to RMB276,849.15) available as at December 31, 2020 for utilization by the Group to reduce the existing level of contributions as described in paragraph 26(2) of Appendix 16 to the Listing Rules.

The above additional information does not affect any other information contained in the 2020 Annual Report. Save as disclosed in this announcement, all other information in the 2020 Annual Report remains unchanged.

By order of the Board
SciClone Pharmaceuticals (Holdings) Limited
ZHAO Hong
Executive Director, Chief Executive Officer and President

Hong Kong, December 10, 2021

As at the date of this announcement, the Board comprises Mr. Zhao Hong as executive director, Mr. Li Zhenfu, Dr. Daniel Luzius Vasella, Ms. Lin Shirley Yi-Hsien, Ms. Li Quan, Mr. Shi Cen and Ms. Wang Haixia as non-executive directors, and Dr. Liu Guoen, Dr. Chen Ping, Mr. Gu Alex Yushao and Ms. Wendy Hayes as independent non-executive directors.

* *for identification purpose only*